Poxel reports revenue for the second quarter and first half of 2024, provides business update Page 1

Regulatory News:

POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a business update and announced revenue for the second quarter and first half of 2024.

Thomas Kuhn, CEO of Poxel, stated: “As our exclusive discussions to monetize royalties from sales of TWYMEEG in Japan are now being finalized, the topline results recently obtained by our partner Sumitomo Pharma from the TWINKLE post-marketing clinical trial confirm the product’s profile for type 2 diabetes patients with renal impairment. These results provide a basis for our partner to enter into discussions with the regulatory authorities in Japan to revise the TWYMEEG package insert and, on the appropriateness, to recommend TWYMEEG to Japanese patients with type 2 diabetes and renal impairment.”